Highlights BeiGene, Ltd.

Equities

BGNE

US07725L1026

Real-time Estimate Cboe BZX Other stock markets 02:31:54 2024-05-17 pm EDT			5-day change	1st Jan Change
173.7 ^USD	+1.54%		+7.75%	-3.74%

May. 14	BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024	CI
May. 09	Beigene Q1 Loss Shrinks as Revenue Grows; Company's Shares Nearly 7% Up	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024	May. 14	CI
Beigene Q1 Loss Shrinks as Revenue Grows; Company's Shares Nearly 7% Up	May. 08	MT
Sector Update: Health Care Stocks Lean Lower Pre-Bell Wednesday	May. 08	MT
BeiGene's Q1 Loss Narrows as Revenue Rises	May. 08	MT
Earnings Flash (BGNE) BEIGENE Reports Q1 Revenue $752M	May. 08	MT
BeiGene, Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08	CI
BeiGene, Ltd. Anticipates Opening of Biologics Manufacturing Facility and Clinical R&D Center at the Princeton West Innovation Campus in Hopewell, New Jersey, in July 2024	May. 08	CI
Amgen Posts Higher 1Q Revenue, Swings to Loss	May. 02	DJ
BeiGene Says Tislelizumab Gets European Commission's Approval to Treat Non-Small Cell Lung Cancer; Shares Rise	Apr. 23	MT
BeiGene Says Tislelizumab Gets European Commission's Approval to Treat Non-Small Cell Lung Cancer	Apr. 23	MT
BeiGene, Ltd. Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer	Apr. 23	CI
BeiGene Opens New Factory in Guangzhou for Antibody-Drug Conjugates	Apr. 10	MT
Beigene Shrinks Loss by 56% in 2023	Mar. 29	MT
Tech Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Slightly Lower in Friday Trading	Mar. 22	MT
Beigene's Esophageal Cancer Drug Gets US FDA Nod	Mar. 15	MT
BeiGene Gets FDA Approval for Esophageal Cancer Treatment	Mar. 14	MT
BeiGene, Ltd. Receives FDA Approval for TEVIMBRA for Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy	Mar. 14	CI
US FDA approves BeiGene's esophageal cancer therapy	Mar. 14	RE
BeiGene, Max Foundation Providing Brukinsa to Leukemia Patients in Armenia, Nepal as Part of 3-Year Partnership	Mar. 13	MT
BeiGene Shares Rise on First Dosing of Brukinsa	Mar. 13	DJ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights BeiGene, Ltd.

Equities

BGNE

US07725L1026

Highlights

Filters